Darolutamide given in an extended duration was linked with long-term clinical benefit and safety in patients with nonmetastatic castration-resistant prostate cancer.
The addition of olaparib to abiraterone acetate resulted in numerically higher prostate-specific antigen response rates and prolonged time to PSA progression vs abiraterone alone when used in the frontline treatment of patients with metastatic castration-resistant prostate cancer.
The use of zoledronic acid or other bisphosphonates was associated with a significant reduction in risk of fracture in patients with metastatic hormone-sensitive prostate cancer.
Reduced doses of apalutamide did not significantly decrease rates of skin-related adverse effects vs full-dose apalutamide in patients with advanced prostate cancer.